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ABSTRACT: Lens is the avascular tissue in the eye between the aqueous
humor and vitreous. Drug binding to the lens might affect ocular
pharmacokinetics, and the binding may also have a pharmacological role in
drug-induced cataract and cataract treatment. Drug distribution in the lens has
been studied in vitro with many compounds; however, the experimental
methods vary, no detailed information on distribution between the lens
sublayers exist, and the partition coefficients are reported rarely. Therefore,
our objectives were to clarify drug localization in the lens layers and establish
partition coefficients for a wide range of molecules. Furthermore, we aimed to illustrate the effect of lenticular drug binding on
overall ocular drug pharmacokinetics. We studied the distribution of 16 drugs and three fluorescent dyes in whole porcine lenses
in vitro with imaging mass spectrometry and fluorescence microscopy techniques. Furthermore, we determined lens/buffer
partition coefficients with the same experimental setup for 28 drugs with mass spectrometry. Finally, the effect of lenticular
binding of drugs on aqueous humor drug exposure was explored with pharmacokinetic simulations. After 4 h, the drugs and the
dyes distributed only to the outermost lens layers (capsule and cortex). The lens/buffer partition coefficients for the drugs were
low, ranging from 0.05 to 0.8. On the basis of the pharmacokinetic simulations, a high lens-aqueous humor partition coefficient
increases drug exposure in the lens but does not significantly alter the pharmacokinetics in the aqueous humor. To conclude, the
lens seems to act mainly as a physical barrier for drug distribution in the eye, and drug binding to the lens affects mainly the
drug pharmacokinetics in the lens.
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1. INTRODUCTION
Lens is a transparent, avascular organ positioned in the eye
between the aqueous humor and vitreous. The main function
of the lens is to change the focal distance of the eye, which
ensures the formation of a clear image to the retina with
various object distances. The lens consists of the lens capsule,
lens anterior epithelial cell monolayer, and lens fiber cells1
(Figure S1). The lens capsule surrounds the epithelial and fiber
cells of the lens and allows the permeation of even large
molecules to the lens.2−4 The lens epithelial cell layer lies in
the anterior lens and possesses tight junctions.5 The fiber cells,
named for their long length, are differentiated epithelial cells
that have migrated from the anterior lens to the lens equator
and further toward the lens center during lens growth. The lens
fiber cells can be further divided into loosely structured lens
cortex, which consists of the young lens fiber cells, and dense
lens nucleus, which consists of the oldest. The main
components of the lens are water and proteins, mainly various
crystallins, and their concentrations vary between the lens
cortex and nucleus, the cortex having higher water and lower
protein content than the nucleus.1 The lens lipids contain a
high level of cholesterol, and they are mostly associated with
proteins in the cell membranes.6 Thus, the lipid content of lens
also increases from the cortex to the nucleus. For a more
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detailed, yet introductory, description of the anatomy of the
lens, see the Supporting Information.
The role of lens in ocular pharmacology is known to some
extent. First, the lens acts as a physical barrier that limits drug
entrance from the anterior chamber to the vitreous and vice
versa.7 Therefore, drug distribution between the anterior and
posterior parts of the eye becomes easier in aphakic eyes.8,9
Second, drugs may bind to the lens, thereby affecting ocular
pharmacokinetics. Third, the lens is the target tissue in
potential drug treatments of cataract (i.e., lens opacity).10−12
For a pharmacological effect, the drug must diffuse deep
enough into the lens. Studies on anticataract drugs have not
explored the actual drug distribution or binding in the lens,
though the pharmacological effect indicates that at least a low
drug concentration in the target site is achieved. On the other
hand, drug binding to the lens may also result in cataract
formation, for example, with the use of corticosteroids,
phenothiazines, and busulfan.13
Drug distribution to the isolated lenses has been studied
with various compounds, such as pilocarpine,14 chloramphe-
nicol,15 dexamethasone,15 epinephrine,15 pilocarpine,15 tim-
olol,16 and some aldose reductase inhibitors.17 Drug
distribution between the lens capsule, cortex, and nucleus,
however, has not been reported in detail in the literature. One
comprehensive study with 13 small molecular weight drugs
investigated the in vitro drug partitioning to rabbit lens and
linked compound lipophilicity with increased lens-incubate
concentration ratio and uptake rate to the lens.18 This study
also reported concentrations of some drugs in the lens capsule
and body (lens epithelium and fiber cells) and concluded that
lipophilic drugs can penetrate to the lens body and show
higher lens affinity than more polar compounds. In these
studies, the experimental methods vary, and only rarely actual
lens/buffer partition coefficients were reported.
Drug distribution between the lens capsule and the
epithelium−cortex−nucleus has been previously studied with
radiolabeled compounds, necessitating the mechanical iso-
lation of different layers of the lens.14 Imaging mass
spectrometry (IMS) is a novel technique that should enable
analysis of various compounds simultaneously in the lens tissue
at high spatial resolution (≈10 μm).19−21
In the present work, we aimed to study the localization of
various compounds in porcine lens with matrix-assisted laser
desorption/ionization IMS (MALDI-IMS) and fluorescence
microscopy. Furthermore, we determined the lens/buffer
partition coefficients (Kp) for 28 drugs in the isolated porcine
lens with liquid chromatography−mass spectrometry (LC−
MS/MS). Finally, we illustrated the pharmacokinetic role of
lenticular drug distribution with pharmacokinetic simulations.
2. MATERIALS AND METHODS
2.1. Tissue Isolation. Enucleated porcine eyes were
received from a local slaughterhouse and transported to the
laboratory in cooled 25 mM phosphate-buffered saline (PBS)
within 6 h after enucleation. Extraocular tissues were removed
from the isolated eyeballs. Then, the eye was cut open from
limbus and the lens was collected carefully with a spatula. The
lenses were weighed and immediately used in the experiments.
2.2. Extent of Drug Distribution into the Isolated
Porcine Lens. 2.2.1. Preparation of the Cassette Mix. Drug
distribution to the lenses was determined by using a mixture of
32 compounds: the compounds and their chemical descriptors,
vendors, and solvents for stock solutions are listed in ref.22
Lornoxicam was excluded from the mix. Stock solutions [0.5−
10 mg/mL in PBS or dimethyl sulfoxide (DMSO)] were
combined and diluted further with Hanks’ balanced salt
solution (HBSS)−HEPES (25 mM) (pH 7.4). Octanol−water
distribution coefficients of the compounds (log D7.4) and polar
surface areas (PSAs) were previously estimated in silico from
compound structures with ACD/Labs-software (v12, Ad-
vanced Chemistry Development, Inc., Canada).22
2.2.2. Drug Distribution into the Lens: Studies for MALDI-
IMS. 2.2.2.1. Incubation. To determine distribution of cassette
mix drugs in the lens, the isolated porcine lenses (n = 10) were
incubated in 1200 μL of prewarmed drug solution in capped
flat-bottomed polystyrene vials sealed with parafilm at +35 °C
in a horizontal shaker (Heidolph incubator 1000, Heidolph
Elektro GmbH & Co., Germany) at 150 rpm shaking. After 4
h, the buffer was removed from the vials and the lenses were
rinsed with HBSS−HEPES and gently blotted dry. The lenses
were weighed, snap-frozen with liquid nitrogen in flat-
bottomed plastic tubes, and then stored at −80 °C until
sample preparation and analysis with MALDI-IMS. For the
experiment, a smaller set of 16 drugs was used. The final
incubation mixture of drugs consisted of acetazolamide,
ampicillin, atenolol, atropine, betaxolol, carteolol, ciproflocaxin,
ketorolac, lincomycin, nadolol, pilocarpine, pindolol, and
propranolol, each at 10 μg/mL. Also, aztreonam, methazola-
mide, and tizanidine were included at 100 μg/mL. Final
DMSO concentration of the solution was 2%.
2.2.2.2. Tissue Preparation. The frozen lenses were
mounted onto a chuck using an optimal cutting temperature
compound (Sakura Finetek, CA, USA) on the equatorial side.
The lenses were sectioned to 10 μm thickness at −20 °C on a
Leica CM Cryostat (S3050, Leica Microsystems GmbH,
Germany), equipped with a FEATHER Microtome C35
blade (pfm medical, UK), and collected on a cryofilm
(3C16UF, SECTION-LAB Co. Ltd. Yokohama, Japan) by
modified Kawamoto method.23 The film was subsequently
mounted onto a microscopy glass slide using a double-sided
copper tape. The slides were washed twice with 50 mM
ammonium formate for 30 s and dried in a vacuum desiccator.
The sample slides contained three lens sections from the drug
mixture experiment and three blanks. To quantify the amount
of each compound present in incubated lenses, 1 μL of
standard mixture was added on one of the blank lenses using
concentrations of 0.1, 0.5, 2, and 10 μg/mL. First, the internal
standard solution of atropine-d5 (200 ng/mL in 50%
acetonitrile) was sprayed to obtain a 10.2 ng/cm2 correspond-
ing to approximately 10 μg/g in the tissue. Matrix α-cyano-4-
hydroxycinnamic acid (7 mg/mL in 50% acetonitrile
containing 1% trifluoro acetic acid) (Sigma-Aldrich, St.
Louis, MO, USA) was added via spray deposition using 10
passes, flow rate of 100 μL/min, temperature of 77 °C, track
spacing of 2.5 mm, and velocity of 1300 mm/min (HTX
Industries, TM-Sprayer, NC, USA).
2.2.2.3. Fourier Transform-Ion Cyclotron Resonance-IMS.
MALDI Fourier transform-ion cyclotron resonance (FT-ICR)-
IMS was performed using a Bruker 7T solariX XR mass
spectrometer (Bruker Daltonics, Germany) at a 75 μm spatial
resolution. Spectra were collected in positive ion mode in
mass-to-charge ratio (m/z) range of 100−1000, and the
resolution was 61 000 at m/z 307. The compounds and m/z
values ([M + H]+) used were as follows: atropine 290.1751,
propranolol 260.1645, atenolol 267.1703, carteolol
293.18601860, pilocarpine 209.1285, methazolamide
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237.0111, pindolol 249.1598, tizanidine 254.0262, nadolol
310.2013, lincomycin 407.2210, and fluconazole 307.1113.
2.2.2.4. Analysis of FT-ICR Data and Image Processing.
FT-ICR data were read into Fleximaging 4.1 software (Bruker
Daltonics, Germany) and normalized against the d5-atropine
internal standard signal at m/z 295. The drugs were identified
as their [M + H]+ ions. Peak finding was performed using mass
error less than 2.5 ppm. MALDI images for each detected
compound were plotted using a 0.01 μ mass window. From the
images of the individual drugs, the intensity profiles across a 30
pixel (2.25 mm) wide area in anterior−posterior axis were
plotted with ImageJ software (National Institutes of Health,
USA).
2.2.3. Partition Coefficients for Cassette Mix Drugs.
2.2.3.1. Incubation. To determine the Kp values, the
distribution study was conducted as described in Section
2.2.2, but the incubation volume (300 μL), the number of
drugs, and the drug concentrations in the cassette mix were
different. For this experiment, the whole mix of 32 drugs was
used. The test concentrations of the drugs in the cassette mix
were 1 and 10 μg/mL: 1 μg/mL was used for all compounds
except aztreonam, bromfenac, dexamethasone, diclofenac,
fluorometholone, indomethacin, levocabastine, methazolamide,
prednisolone, quinidine, and tizanidine. For these compounds,
a concentration of 10 μg/mL was used. Two different drug
concentrations were used to ensure reliable quantitation in the
LC−MS/MS analyses. The DMSO concentration of the final
mixture was 0.9%. The lenses were stored at −80 °C until
sample preparation and analysis with LC−MS/MS.
2.2.3.2. Sample Preparation for LC−MS/MS. The lenses
were homogenized first with plastic homogenization pestles
and then with ULTRA-TURRAX (model T8, IKA-Werke
GmbH & Co. KG, Germany) in HBSS−HEPES (1 g lens + 9
mL buffer). Lens homogenate (200 μL) was mixed with 400
μL of methanol (Chromasolv LC−MS Ultra, Honeywell
Riedel-de Haen̈, NC, USA), containing internal standards
atenolol-d7 (Toronto Research Chemicals Inc., Canada),
atropine-d5 (Toronto Research Chemicals Inc., Canada),
fluconazole-d4 (Toronto Research Chemicals Inc., Canada),
and lincomycin-d3 (Toronto Research Chemicals Inc.,
Canada) at 24.4 ng/mL each and vortexed. The samples
were centrifuged at 16 060g for 10 min at +4 °C and their
supernatants were collected and stored at −20 °C. On the day
of LC−MS run, the sample supernatants (300 μL) were
filtered through a Captiva ND lipid-plate (Agilent Technolo-
gies, CA, USA) to a Captiva 96 deep well collection plate
(Agilent Technologies, CA, USA) by centrifugation at 1560g
for 40 min at +4 °C. Duplicate standards (eight levels, 5−1000
ng/mL) and triplicate quality control (QC) samples (50, 250
and 1000 ng/mL) were prepared from cassette mix working
solutions in a similarly diluted lens homogenates as the actual
samples.
2.2.3.3. LC−MS/MS Analysis. For detailed description of the
LC−MS/MS acquisition method, see ref 22. For the LC−MS/
MS analyses, the lens samples were run in two separate analysis
batches with independent standards and QC samples. The
resulting data were analyzed with Agilent MassHunter
Quantitative Analysis software (vB.09.00, build 9.0.647.0,
Agilent Technologies, CA, USA). Internal standards were
used in the calculations. The calibration curves were calculated
from duplicate standard series, one of which was run in the
beginning and the other at the end of each analysis. Quadratic
fitting with 1/x weighing was used. The criteria for calibration
curve and QC acceptance were 80−120% accuracy of mean for
≥66.7% of calibration levels and at LLOQ, 80−120% accuracy
for ≥66.7% of individual QCs and QC levels and <20%
coefficient of variation for ≥66.7% of QC levels. The selectivity
criterion of ≥3-fold response ratio of LLOQ to matrix-based
blank sample was employed.
2.2.3.4. Calculation of Lens/Buffer Partition Coefficients
(Kp). From the LC−MS/MS results, Kp values were first
calculated using the total lens volume (eq 1)
= =
−
K
C
C
m V
C m V
/
/p
lens,4h
inc,4h
lens,4h lens
inc,init lens,4h inc (1)
where Clens,4h is the drug concentration in the lens at 4 h (ng/
mL), Cinc,4h is the drug concentration in the incubate at 4 h
(ng/mL), mlens,4h is the drug amount in the lens at 4 h (ng),
Vlens is the lens volume (mL) (calculated with the actual lens
mass and lens density of 1.183 g/mL24), Cinc,init is the initial
drug concentration in the incubate (ng/mL), and Vinc is the
volume of the buffer (mL).
The drug concentration in the incubate at 4 h was calculated
by using the initial drug concentration in the buffer (Cinc,init),
buffer volume (Vinc), and drug amount in the lens at 4 h
(mlens,4h) instead of the measured concentration in the incubate
because the concentration in the incubate showed very little
decrease (<5−10%) during the incubation. Kp values were also
calculated with the actual lens volume into which the
compounds distribute based on the MALDI IMS data (true
distribution volume instead of the total lens volume) (see the
Supporting Information). The same approximation for the
volume of distribution was assumed for all cassette mix
compounds.
2.3. Distribution Patterns of Fluorescent Dyes within
the Lens. 2.3.1. Fluorescent Dyes. The distribution patterns
of the compounds in the porcine lenses were studied with
three fluorescent dyes with varying lipophilicities. Rhodamine-
B and fluorescein sodium (Sigma-Aldrich) were dissolved into
HBSS−HEPES (pH 7.4) at 1 mg/mL concentration. Rhod-
amine-123 (Sigma-Aldrich) was first dissolved into ethanol (10
mg/mL) and then diluted in HBSS−HEPES (pH 7.4) to reach
0.1 mg/mL (final ethanol concentration was 1%).
2.3.2. Incubation. The distribution studies with fluorescent
dyes were conducted separately for each dye, as described in
Section 2.2.2, with an incubation volume of 1200 μL. After
incubation, the lenses were rinsed, blotted dry, frozen in an
optimal cutting temperature compound (Sakura Finetek, SA,
USA) in plastic tubes with chilled 2-propanol, and stored at
−20 °C until cryosectioning.
2.3.3. Fluorescence Microscopy. The lenses were sectioned
to a thickness of 10 μm at −20 °C with Leica CM cryostat
(Leica 3050S, Leica Microsystems GmbH, Germany)
equipped with a FEATHER Microtome C35 blade (pfm
medical, UK) and collected on a SuperFrost Plus adhesion
microscope slide (Thermo Fisher Scientific, MA, USA). The
tissue slices were imaged with a fluorescence microscope
(Zeiss Axio Imager M2, Carl Zeiss Microscopy GmbH,
Germany) equipped with filters 470 nm (65HEAF488) and
590 nm (64HEmPlum) filters and Axiocam MRm camera
(Carl Zeiss Microscopy GmbH, Germany) using a 2.5-fold
magnification. Exposure times were 600 ms for fluorescein
sodium, 600 ms for rhodamine-B, and 1 s for rhodamine-123.
Individual images of the lens sections were merged together
manually with GNU image processing software (v2.10.6).
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2.4. Pharmacokinetic Simulations. 2.4.1. Model Struc-
ture and Parameters. A pharmacokinetic simulation model
for rabbit was built for topical timolol instillation based on the
model of Ranta et al.25 The lens compartment, separate from
the reservoir compartment, was added to the model (Figure 1).
The unknown parameter values for timolol distribution
clearance between aqueous humor and lens (QLENS), Kp, and
clearance from tear fluid to cornea (CLTF,CO) were obtained by
adjusting the values manually until the simulated concentration
in the lens matched with in vivo data on timolol distribution to
the rabbit lens.26 Finally, the distribution clearance between
the aqueous humor and the reservoir (QRESERVOIR) and the
volume of the reservoir (VRESERVOIR) were adjusted to match
the corresponding parameters in the original model. For details
of the model building and parameters, see the Supporting
Information. STELLA software (v8.1.1, isee systems) was used
to construct the simulation model.
2.4.2. Simulations. Kinetic simulations were carried out to
estimate how drug partitioning into the lens might affect ocular
pharmacokinetics after single and multiple doses of eye drops.
In the simulations, a single and repeated dosing (every 24 and
8 h) of 125 μg of timolol (0.5%, 25 μL) were used. The run
time was 7 days and the delta time was 0.5 min. Simulations
were run with Kp values of 0.35, 1.05 (3-fold increase), and 3.5
(10-fold increase) to see the potential impact of lens
partitioning on ocular pharmacokinetics.
3. RESULTS
3.1. Lens Integrity. The lens should retain its integrity
during the incubation with drugs. Therefore, the integrity was
evaluated by monitoring the lens mass (Figure S2) and
appearance at different times. During 4 h of incubation, the
mass was retained at 469 ± 55.8 mg, and no change in the lens
mass was observed. Furthermore, the lenses did not show
damage or swelling during the experiments. However, in a
preliminary experiment, a clear decrease in the lens mass was
seen at longer incubation times. The remaining mass,
compared to the original, was 81.3 ± 11.0% (n = 2) at 12 h
and 67.2 ± 16.8% (n = 10) at 24 h of incubation (Figure S2).
Furthermore, after 4 h, the lens capsule and cortex began
swelling and came off by 12 h. For this reason, longer
incubations were not feasible and incubations of 4 h were used
in the experiments.
3.2. Drug and Dye Distribution Patterns in the Lens.
The distribution patterns of the cassette mix drugs in the
porcine lens were evaluated using MALDI-IMS. Eleven
(atenolol, atropine, carteolol, fluconazole, lincomycin, meth-
azolamide, nadolol, pilocarpine, pindolol, propranolol, and
tizanidine) out of the 16 compounds gave acceptable signals
when standard solution was loaded on a blank lens section
(Figure S3). When the drug amount in the pipetted standard
solutions exceeded 2 ng per spot, the internal standard
atropine-d5 signal was suppressed (Figure S4).
In the lens samples, atropine, pilocarpine, pindolol,
propranolol, and tizanidine (in silico predicted log D7.4 range
from −1.09 to 2.04) showed distribution only in the capsule
and cortex of the lens but not in the nucleus (Figure 2). The
posterior rim showed 1.2- to 2-fold higher intensities than the
anterior rim (Figure 3). In general, the signal intensity−
distance profiles for the drugs were similar. For aztreonam,
lincomycin, methazolamide, and nadolol, the signals at their
m/z were detected in the drug-incubated lens sample, but also
in the blank lenses. This indicates that the signals originated
from some endogenous compounds with the same m/z within
our experimental error. These compounds were therefore
excluded from further analysis. In the average spectrum taken
from the lens posterior surface (thickness 1 mm), the intensity
measured for d5-atropine was 850 and for atropine 290 (Figure
Figure 1. Simulation model for timolol distribution to the lens after
topical dosing, extended from ref 25. VTF, tear fluid volume; CLTF,CJ,
clearance from tear fluid by conjunctival absorption; CLTT, clearance
from tear fluid by tear turnover; CLdrain, clearance from tear fluid by
drainage of the instilled solution; CLTF,CO, clearance from tear fluid by
corneal absorption; kD, corneal desorption rate constant; VAQ,
aqueous humor volume; kel, elimination rate constant; QRESERVOIR,
distribution clearance between aqueous humor and reservoir;
VRESERVOIR, reservoir volume; Kp, lens/buffer partition coefficient;
QLENS, distribution clearance between aqueous humor and the lens;
VLENS, lens volume.
Figure 2. Drug distribution in a porcine lens after 4 h in vitro incubation. m/z signals across a lens section were obtained with MALDI-IMS and
normalized to internal standard atropine-d5 signal. A = anterior lens pole, P = posterior lens pole.
Figure 3. Relative drug distribution along the anterior−posterior axis
in a porcine lens after 4 h in vitro incubation.
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S5). On the basis of the ratio, the concentration of atropine is
estimated to be 3.4 μg/g.
Distribution studies were also performed with fluorescent
dyes with different lipophilicities. The dyes did not penetrate
into the lens nucleus in 4 h and, thus, fluorescence imaging
data were in accordance with the MALDI-IMS results.
Rhodamine-B (experimental log D7.0 = 2
27) distributed slightly
deeper into the lens cortex than rhodamine-123 (experimental
log D7.0 = 0.4
28) and fluorescein sodium (experimental log D7.0
= 0.129) (Figure 4).
3.3. Lens/Buffer Partition Coefficients. Lens/buffer Kp
values were obtained for 28 out of 32 drugs by analyzing the
drug amounts in whole porcine lenses with LC−MS/MS. The
whole lens volume was used in the calculations (eq 1). The Kp
values were <1.0 for all compounds and <0.5 for most of them
(Figure 5). The range was from 0.047 (methazolamide) to
0.762 (propranolol).
The apparent volume of drug distribution was estimated
from the MALDI-IMS data. On the basis of the MALDI-IMS
images of atropine, pindolol, propranolol, pilocarpine, and
tizanidine, the five drugs had a similar spatial distribution
despite having different log D7.4 values, and we estimated that
the drugs distributed to 27.1% of the total lens volume (see the
Supporting Information and Equation S1). This volume was
used for all cassette mix compounds. The use of this volume in
the calculations resulted in higher Kp values (Figure 5), ranging
from 0.172 (methazolamide) to 2.810 (propranolol). Still, only
six compounds (propranolol, quinidine, voriconazole, betax-
olol, tizanidine, and diclofenac) had Kp > 1.
The Kp values did not show correlation with in silico-
predicted log D7.4 within the entire group of drugs (Figure 6,
panel A), even though the highest Kp values were seen for
compounds with log D7.4 > 0. Furthermore, the series of β-
blockers nadolol, atenolol, carteolol, pindolol, betaxolol, and
propranolol showed increasing Kp with increasing log D7.4
(Figure 6, panel A). PSA showed an inverse correlation with Kp
in the whole group of drugs (Figure 6, panel B).
We did not obtain Kp values for acyclovir, ganciclovir,
aztreonam, and fluorometholone because their quantitative
analyses did not meet the acceptance criteria.
3.4. Pharmacokinetic Simulations. Pharmacokinetic
simulations of a single topical timolol eye drop were carried
out with three lens/buffer Kp values (0.35, 1.05, and 3.5) to
see, whether drug partitioning to the lens affects drug
concentrations or area under the curve (AUC) values in the
aqueous humor and the lens. The simulations were also run
with repeated dosing of eye drops at 8 and 24 h intervals.
3.4.1. Single Topical Dose. Neither the simulated peak
concentration nor the shape of the concentration−time curve
in aqueous humor were notably affected by the lens Kp (Table
1; Figure 7, panel A). In the lens, the peak concentration with
Kp of 0.35 was 0.28 μg/mL, and with Kp values of 1.05 and 3.5,
it was 1.3- and 1.5-fold higher, respectively (Table 1; Figure 7,
panel B). Also, AUC0−14d in the lens increased from 111 μg·
min/mL 3- and 10-fold, when Kp was increased from 0.35 to
1.05 and 3.5, respectively. At 8 h, the drug concentration in
aqueous humor was close to 0 regardless of the Kp values,
whereas in the lens, the concentration was >0.1 μg/mL with all
Kp values. The drug concentration in the lens remained above
0 for roughly 1, 2, and 8 days with Kp values of 0.35, 1.05, and
3.5, respectively.
3.4.2. Repeated Dosing. With every 24 h dosing, the peak
concentration in aqueous humor did not change considerably
with increasing Kp values (Table 1; Figure 8, panel A).
Between the doses, the concentration in aqueous humor
dropped to zero with all Kp values. In the lens, the peak
concentration at steady state was 0.28 μg/mL with Kp of 0.35,
and it increased to 1.5- and 3.4-fold with Kp values of 1.05 and
3.5, respectively (Table 1; Figure 8, panel B). With the lowest
Kp (0.35), the concentration in the lens reached 0 between the
doses, whereas with Kp values of 1.05 and 3.5, the minimum
concentrations at steady state were 0.08 and 0.58 μg/mL,
respectively.
Figure 4. Distribution of fluorescein (log D7.0 = 0.1), rhodamine-123
(log D7.0 = 0.4), and rhodamine-B (log D7.0 = 2) into the porcine lens
in vitro after 4 h incubation. A = anterior lens, P = posterior lens.
Figure 5. In vitro lens/buffer partition coefficients (Kp) for the drugs after 4 h incubation with the porcine lens. The Kp values were calculated
based on the imaged volume of distribution and total anatomical volume of the lens. Mean ± standard deviation (SD), n = 10, except for atenolol n
= 5.
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With every 8 h dosing, neither the peak nor the minimum
concentration in aqueous humor changed markedly with
increasing Kp (Table 1; Figure 8, panel C). In the lens, the
peak concentrations at steady state increased from 0.34 μg/mL
(Kp 0.35) to 2- and 7-fold with Kp values of 1.05 and 3.5,
respectively (Table 1; Figure 8, panel D). With a Kp of 0.35,
the minimum concentration at steady state was 0.11 μg/mL,
and it increased 5- and 20-fold with Kp values of 1.05 and 3.5,
respectively.
4. DISCUSSION
Drug binding to the lens has a role in ocular pharmacokinetics,
pharmacology, and drug delivery. To our knowledge, this is the
first study that explores lenticular drug distribution using a
wide range of drugs and dyes. We showed that the extent of
drug distribution to the porcine lens during 4 h in vitro
incubation is low regardless of the compound properties. The
Kp values of all drugs ranged from 0.05 to 0.8. Furthermore,
the pharmacokinetic simulations indicated that drug partition-
ing to the lens does not affect drug concentrations in the
aqueous humor but increases the AUC and drug concen-
Figure 6. Relationship between in vitro lens/buffer partition coefficient (Kp) (mean ± SD, n = 5−10) and compound lipophilicity (log D7.4 and
PSA) for all of the studied compounds and a series of β-blockers nadolol, atenolol, carteolol, pindolol, betaxolol, and propranolol. The Kp values
were calculated by using both the image-based distribution volume and the total anatomical volume of the lens.
Table 1. Simulated Timolol Concentrations and AUCs in the Aqueous Humor and Lens with Various Lens/Buffer Partition
Coefficients (Kp) and Dosing Schemes
Kp
0.35 1.05 3.5
single dose of 125 μg (25 μL) aqueous humor Cmax (μg/mL) 2.79 2.79 2.79
AUC0−14days (μg·min/mL) 318 318 318
lens Cmax (μg/mL) 0.28 0.36 0.42
AUC0−14days (μg·min/mL) 111 333 1111
125 μg (25 μL) once daily aqueous humor Cmax,ss (μg/mL) 2.79 2.79 2.80
Cmin,ss (μg/mL) 0.00 0.00 0.00
lens Cmax,ss (μg/mL) 0.28 0.43 0.95
Cmin,ss (μg/mL) 0.00 0.08 0.58
125 μg (25 μL) three times daily aqueous humor Cmax,ss (μg/mL) 2.80 2.81 2.81
Cmin,ss (μg/mL) 0.01 0.02 0.02
lens Cmax,ss (μg/mL) 0.34 0.80 2.42
Cmin,ss (μg/mL) 0.11 0.55 2.16
Figure 7. Simulated timolol concentrations in the aqueous humor and lens after a single 125 μg topical dose to rabbit with different lens/buffer
partition coefficient (Kp) values. The dots present observed timolol concentrations in vivo
26 while the lines present the simulated ones. For aqueous
humor, the lines with various Kp values overlap each other.
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trations in the lens. It seems that drug partitioning to the lens
has pharmacological significance only if the site of drug action
or toxicity is in the lens.
Lens partition coefficients with a broad set of compounds
using the same method have not been presented previously. In
general, the Kp values in previous reports have ranged from
about 0.3 (pilocarpine15) to 8 (aldose reductase inhibitor CT-
11217). The results of this study are roughly in line with
previously published or recalculated in vitro Kp values. As
examples from previous literature, pilocarpine has a Kp of 0.3−
1.0 in rabbit14 and human15 and dexamethasone 0.3−0.5 in
human.15 Our Kp values for pilocarpine (0.145) and dexa-
methasone (0.102) are slightly lower, but in the same range as
the previous data. Small differences may be caused by test
conditions (e.g., incubation time) and species differences in
lens biochemistry (e.g., protein content11). Tang-Liu et al.18
reported higher lens/buffer Kp values, more than 5, for
lipophilic compounds, but they used a long incubation time of
24 h. In our experience, longer than 4 h incubation times
resulted in the loss of lens integrity that may lead to
overestimation of drug distribution into the lens.
For most compounds, the incubation time of 4 h was long
enough to reach the concentration equilibrium between the
incubate and the lens (see Figure S7). Some compounds such
as ciprofloxacin and diclofenac would have required longer
incubation time to reach true equilibria, which might lead to
underestimation of their Kp values. However, it is evident that
drug distribution to the lens differs substantially from drug
distribution into the iris and ciliary body. The low Kp values for
the lens are in line with ocular pharmacokinetics in vivo, as
concentrations of several drugs (timolol, pilocarpine, atropine,
and dexamethasone) in the lens in vivo are much lower than in
the aqueous humor, iris, and ciliary body.14,19,26,30,31 Low Kp
values are also in line with a report by del Amo et al.,32 which
demonstrated that the ocular volume of distribution of
intravitreally injected 40 small and 12 macromolecular drugs
was within a narrow range, close to the anatomical volume of
the vitreous.
Interestingly, the drugs and dyes consistently distributed
only to the capsule, epithelium, and cortex of the lens, but not
to the lens nucleus. Similar findings have been reported for
radiolabeled timolol in vivo33 and arginine vasopressin and
progesterone in vitro.18 The distribution pattern may be
explained by the weaker barrier properties in the lens capsule
and cortex as compared to the lens nucleus. The lens capsule
allows even permeation of macromolecules, such as dextrans
(up to 150−160 kDa),2,3 and proteins.4 Thus, it does not
hinder the distribution of the small molecular weight drugs to
the lens epithelium and cortex. The lens cortex consists of the
younger, softer lens fiber cells, whereas the older fiber cells are
tightly packed in the lens nucleus. This change in the
organization of the lens fibers, higher protein concentration
in the nucleus, and the decrease in extracellular space probably
hinder the permeation of even lipophilic small molecular
weight drugs to the lens nucleus. Overall, the tight proteina-
ceous structure and low lipid content of the lens seem to result
in low Kp values. The Kp values in total tissue volume were
<1.0, and even in the case of true distribution volume, the Kp
values exceeded 1.0 only in few cases. Relatively low lipid
content of the lens may explain the correlation and inverse
correlation of Kp with log D7.4 and PSA, respectively, at low
overall levels of Kp values. In the whole heterogeneous group,
the correlation with log D7.4 was not clear, even though we
used compounds with distinct levels of hydrophilicity and
lipophilicity. For example, the log D7.4 values spanned from
−5.10 (methotrexate) to +4.19 (brinzolamide). Moreover, in
the anterior lens, the lens epithelium with tight junctions33
may slow down drug diffusion to the lens fiber cells.
Accordingly, the intensities of MALDI-IMS signals were
higher in the posterior than in the anterior lens.
In the pharmacokinetic simulations, drug partitioning to the
lens virtually did not affect the drug concentration in the
aqueous humor despite repeated dosing and a Kp value of 3.5.
Figure 8. Simulated timolol concentrations in the aqueous humor and lens after repeated topical dosing with different lens/buffer partition
coefficients (Kp). For aqueous humor, the lines with various Kp values overlap each other.
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The reason for this is the relatively slow intercompartmental
clearance between the lens and aqueous humor over-run by the
faster elimination from the aqueous humor. The partitioning to
the lens did however increase the AUC and drug
concentrations in the lens substantially even after a single
topical dose. The change was especially prominent with
repeated dosing. On the basis of the simulations, drug
partitioning to the lens affects mainly the drug exposure in
the lens, but not in the aqueous humor, and hypothetically also
not in the surrounding tissues such as iris, ciliary body, and
trabecular meshwork.
To our knowledge, MALDI-IMS has not been used before
to analyze drug-like compounds in the ocular lens. With IMS,
the relative and absolute quantitation suffers markedly from
competition and suppression caused by endogenous com-
pounds, mainly lipids and salts. However, signal intensity
normalization and the use of isotope-labeled standards can
enhance the quantitation,34 and at the very least, IMS can
generate qualitative data on drug distribution within the tissue.
In our MALDI-IMS analysis, increasing concentrations of the
drug mix standards caused partial suppression of the internal
standard (d5-atropine) signal. Thus, despite the use of an
isotope-labeled standard, no exact quantitative concentrations
were obtained. However, it is reasonable to estimate that at low
concentrations, the ratio of drug and d5-atropine reflects the
concentration of the drug in the tissue. Thus, we used the
relative signal of each drug across the lens section to estimate
the distribution patterns. To conclude, the MALDI-IMS is a
powerful new tool in lenticular drug distribution studies, and
possibly also in other ocular pharmacokinetic investigations.
Further work is needed to reach accurate calibration curves
and quantitative analyses of the drugs in the lens tissue
sections.
To conclude, we have determined the in vitro partition
coefficients (Kp) and the distribution patterns of various drugs
in the porcine lens. The extent of lenticular distribution drug
distribution is low (Kp < 1) and the drugs do not distribute to
the lens nucleus in 4 h. Furthermore, it seems that the impact
of drug distribution to the lens has minimal impact on drug
concentrations in the aqueous humor, while lenticular
distribution is obviously an important factor for drug if the
drug has effects in the lens. It seems that drug concentrations
in the aqueous humor are determined by drug absorption to
the anterior chamber and its clearance from the aqueous
humor (via trabecular meshwork and blood flow of anterior
uvea). However, the lens forms a dense barrier between the
anterior chamber and the vitreous, thereby limiting drug
distribution from the anterior chamber to the vitreous and vice
versa.
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